

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 8, 2017 (December 5, 2017)

Cumberland Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Tennessee

(State or other jurisdiction of incorporation)

001-33637

(Commission File Number)

62-1765329

(I.R.S. Employer Identification No.)

2525 West End Avenue, Suite 950, Nashville, Tennessee

(Address of principal executive offices)

37203

(Zip Code)

Registrant's telephone number, including area code: (615) 255-0068

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

Cumberland Pharmaceuticals Inc. (the "Company"), is a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care. Company representatives began meeting with investors utilizing the presentation which is furnished as [Exhibit 99.1](#) and is also on the Company's website.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

December 8, 2017

By: Michael Bonner

Name: Michael Bonner

Title: Chief Financial Officer

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
<u>99.1</u>	Investor Presentation



CUMBERLAND[®]
PHARMACEUTICALS

Investor Presentation

Safe Harbor Statement

This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the date of this presentation and are subject to uncertainty and changes in circumstances. Given these uncertainties, you should not place undue reliance upon these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause the actual results of Cumberland Pharmaceuticals to be materially different from those reflected in such forward-looking statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in our Form 10-K and Form 10-Q Reports on file with the SEC. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All statements contained in this presentation are made only as of the date of this presentation



Company Overview

- **Specialty pharmaceutical company**
 - Portfolio of **seven** FDA approved products
 - Promoted by **two** national sales forces
- Several **near-term catalysts** for new growth opportunities
- **Four Phase II products** in development with upcoming study milestones
- Proven record of **successful** product development and product acquisition
- **Strong financial position** and positive net cash flows from operations



Marketed Brands



HOSPITAL

Acetadote®
(Acetaminophen Toxicity)

Caldolor®
(Pain and Fever)

Vaprisol®
(Hyponatremia)

Ethyol®
(Amifostine)

Totect®
(Dexrazoxane)



GASTROENTEROLOGY

Kristalose®
(Acute/Chronic Constipation)

Omeclamox®-Pak
(H. pylori)



IV ACETADOTE®

- IV treatment for **acetaminophen overdose**
- Developed and registered by **Cumberland**
- Acetaminophen is the **leading cause of poisoning in the U.S.***
- Acetadote now **standard of care**
- Cumberland offers both Brand and Authorized Generic
- Favorable court rulings upholding patents
- Maintaining **significant market share**


*National Poison Data System, American Association of Poison Centers



CALDOLOR®

- Patented, **injectable formulation of ibuprofen**
- Developed and registered by **Cumberland**
- **First injectable** approved in the US for pain & fever
- Unresolved pain remains **leading cause for hospital readmissions**, with a total **market potential of over 700M units***
- Significant data supports pre-op management of inflammation
- **Pediatric labeling** approved by FDA and launched

*Symphony Source Health





Ethyol[®] (amifostine)^{for} Injection

- Re-launch of an FDA-approved **oncology hospital brand**
- **Protects against** the harmful effects of cancer treatments
- **Protects the patient's healthy tissue, not the tumor**
- Indicated for use with **head & neck and ovarian cancers**
- Potential to become Cumberland's **largest selling brand**



- FDA-approved **oncology hospital brand**
- Indicated to treat toxic effects of **extravasation** (leakage) associated with anthracycline chemotherapy
- Can **limit damage** from extravasation and enable patients to continue treatment
- Anthracyclines are **widely used** in the treatment of breast cancer, soft tissue sarcomas, and lymphomas



Portfolio Expansion Strategy



IDENTIFY

Late Stage Candidates



ACQUIRE

*Under-Promoted,
Approved Brands*



EXPAND

Existing Products



DEVELOP

Early-Stage Candidates

**PRODUCT
PORTFOLIO**



Ifetroban

Overview

- A **potent, selective** antagonist of thromboxane receptor (TPr)
- **Initially developed by Bristol-Myers Squibb** as an anti-platelet agent
- **Safety is well-established** in 26 clinical studies with **over 1,300 subjects**
- Cumberland is collaborating with Vanderbilt, Harvard, Scripps and other academic centers
- Cumberland successfully manufactures **both IV and oral formulations**



Rationale for Ifetroban

Ifetroban Inhibits The Thromboxane Receptor (TPr):

- Antagonist of smooth muscle contraction, platelet aggregation, and inflammation
 - New data also demonstrates impact on fibrosis
- **Hepatorenal Syndrome:** Renal Vasoconstriction, Liver Inflammation, & Fibrosis
 - **Aspirin Exacerbated Respiratory Disease (AERD):** Airway Constriction, Vasoconstriction, & Cellular Infiltration/Inflammation
 - **Systemic Sclerosis:** Vasoconstriction, Autoimmune Inflammatory Process, & Fibrosis
 - **Portal Hypertension:** Endothelial Dysfunction, Liver Fibrosis, & Inflammation



Hepatoren® in HRS

- Patients with HRS have **severe multi-organ dysfunction**
 - **No FDA approved treatment** for this unmet medical need
 - **Orphan Drug candidate**, with an estimated patient population of 175,000
-
- Cumberland has **completed initial Phase IIA study**
 - Ifetroban was **well-tolerated** across all doses with **no safety concerns**
 - Showed **signals of improved kidney function**



Boxaban® in AERD

- **Chronic condition** characterized by asthma, sinus infections, and nasal polyps
 - **No FDA approved treatment** for this unmet medical need
 - Potential **Orphan Drug candidate**
-

- Cumberland has **completed initial Phase IIA study**
 - Ifetroban was **well-tolerated** with **no safety concerns**
 - Showed **signals of efficacy** and improved respiratory function



Vascularan® in SSc

- **Chronic, life-threatening** multi-system autoimmune
- **Highest death rate** of any autoimmune disease
- **No FDA approved treatment** for this unmet medical need
- **Orphan Drug candidate**, with an estimated patient population of 165,000
- Cumberland is currently **conducting an initial Phase IIA study**



Portaban™ in PH


- The **most serious** complications of **liver cirrhosis**
- **Median survival is 6 years** from diagnosis
- **No FDA approved treatment** for this unmet medical need
- **Orphan Drug candidate**, with an estimated patient population of 100,000
- Cumberland is currently **conducting an initial Phase IIA study**



Ifetroban

Development Pipeline

Existing Safety Profile of >1,300 Patients



Financial Overview

(\$ in millions)

	3Q 2017	YTD 2017
Net Revenues	\$11.2	\$29.5
Cost of Products Sold	<u>2.2</u>	<u>5.2</u>
Gross Profit	\$9.0	\$24.3
Selling & Marketing	\$6.2	\$16.2
Research & Development	0.9	2.9
General Administrative	2.1	6.6
Amortization	<u>0.6</u>	<u>1.8</u>
Operating Income (Loss)	(\$0.8)	(\$3.2)
Adjusted Earnings	\$0.1	\$0.4
Adjusted Earnings Per Share	\$0.01	\$0.02



Summary Balance Sheet

(\$ IN MILLIONS)

FY as of Sept 30, 2017

TOTAL ASSETS	\$90.4
CASH & SECURITIES	50.1
TOTAL DEBT	8.0
RETAINED EARNINGS	12.5
TOTAL EQUITY	65.1

**Continued Share Repurchase Program*
**Tax carry forward credits of \$44 million available*



Cumberland

Moving Forward



Diverse product portfolio **focused in large and growing markets**



Proven **development and commercialization capabilities**



Various initiatives in place to support **near-term growth**



Four Phase II products in development with upcoming study milestones



Strong network of **strategic partnerships**



Strong financial position with positive net cash flows from operations





CUMBERLAND[®]
PHARMACEUTICALS

Investor Presentation



Appendix



- **Unique** crystalline formulation of lactulose
- Prescription strength laxative
- **Clinically proven** increases in patient satisfaction
- Acquired from Mylan Laboratories
- Repositioned to reflect **branded status**
- New pricing allowed co-pay support
- Expanding **Managed Care coverage**





- IV treatment for **hyponatremia**
- Patented, branded hospital product
- Delivered in a pre-mixed bag
- Promotes free water secretion in hospitalized patients suffering from an imbalance of sodium and water levels
- Condition results from a variety of critical care conditions including **ICU, neurology, nephrology, & oncology**
- Acquired from Astellas



Omeclamox®-Pak

H. pylori Treatment
for patients with duodenal ulcer disease

	Omeclamox®-Pak	PrevPac®	Pylera®
Number of Prescriptions/Co-Pays	1/1	1/1	2/2
Days of Therapy	10	10-14	10
Doses Per Day	2	2	4
Pills Per Day	8	8	14
Total Pill Burden	80	112	140

- **Newest treatment** for Helicobacter pylori (H. pylori) a frequent cause of stomach ulcers
- A triple therapy brand
 - Omeprazole (Prilosec)
 - Clarithromycin
 - Amoxicillin
- **Requires fewer pills** than other products that treat H. pylori
- **Shorter course of therapy** enhances compliance



Partnership Strategy Slide

Streamline Operational Effectiveness and Expanding Market Penetration via Partnerships



U.S. distribution
partnership with
Cardinal Health



Co-Promotional partnership
to **expand our hospital
coverage across the U.S.**



Strategic alliance for
**brand representation
with the U.S.**



Co-Promotional partnership
to **expand medical
specialties covered** in
support of Kristalose



International Network

Bringing our medicines to patients throughout the world through a growing network of distinguished international partners

